A. Quillet

发表

Surveillance of waiting times for access to treatment: a registry-based computed approach in breast cancer care.

G. Defossez, P. Ingrand, A. Quillet, 2016, European journal of cancer care.

Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers

G. Defossez, P. Ingrand, A. Quillet, 2018, BMC Cancer.

Évaluation de la satisfaction des patientes de leur reconstruction mammaire après mammectomie

A. Quillet, G. Dagregorio, V. Huguier, 2015 .

Drug‐induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database

J. Houeto, M. Pérault-Pochat, J. Neau, 2017, Fundamental & clinical pharmacology.

An improved electrotransfection method using square shaped electric impulsions.

D. Fradelizi, F. Presse, C. Marchiol-Fournigault, 1988, Biochemical and biophysical research communications.

Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B expression. Direct demonstration using beta 2-microglobulin-transfected Daudi cells.

H. Ploegh, A. Harel-Bellan, D. Fradelizi, 1988, Journal of immunology.

Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6.

A. Harel-Bellan, T. Tursz, R. Demars, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.

A. Harel-Bellan, H. Wakasugi, J. Bertoglio, 1986, Journal of immunology.

Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.

D. Fradelizi, A. Faille, N. Jabrane-Ferrat, 1990, British Journal of Cancer.

Lack of reconstitution of nude mice alloreactivity by purified interleukin 2 and induction of non-H-2-specific effector cells by crude supernatants.

A. Harel-Bellan, D. Fradelizi, C. Marchiol, 1987, Cellular immunology.

Effects of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) on the expression of LFA-1 in the moderate phenotype of leukocyte adhesion deficiency (LAD)

M. Dimanche-Boitrel, C. Griscelli, A. Fischer, 1989, Journal of Clinical Immunology.

Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers

G. Defossez, P. Ingrand, A. Quillet, 2018, BMC Cancer.

Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database

M. Pérault-Pochat, A. Ferru, S. Favrelière, 2018, Fundamental & clinical pharmacology.

Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.

D. Fradelizi, A. Faille, F. Calvo, 1990, British Journal of Cancer.